Clinical trials
Evans Syndrome clinical trials
Below are recruiting evans syndrome clinical trials, each written for real people, not researchers. We’re tracking 6 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06014775RecruitingPhase 2
Anti-CD38 Antibody for Evans syndrome
This trial tests a new drug called an anti-CD38 antibody for people with Evans syndrome, a rare condition where the immune system attacks blood cells. It is for adults whose disease is active and hasn't improved with standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT04993885RecruitingPhase 2
Avatrombopag for adults with immune low platelets
This trial studies avatrombopag to raise platelet counts in adults with immune thrombocytopenia (ITP) caused by autoimmune conditions. It may help reduce bleeding risk when platelet levels are very low.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05937828Recruiting
Caring for children with autoimmune blood disorders in France
This study follows children and teens who have certain autoimmune blood conditions to better understand their illness. It may help doctors learn how these conditions behave over time and improve care.
AmiensAges Up to 17 years - NCT07175493RecruitingPhase 1/Phase 2
CM336 for relapsed or refractory autoimmune cytopenia
This study tests a new drug called CM336 for people whose immune system mistakenly attacks their own blood cells (autoimmune cytopenia) and hasn't been controlled by other treatments. The goal is to see if CM336 can safely help improve blood cell counts.
Zhengzhou, HenanAges 18 years+ - NCT07441525RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat autoimmune blood diseases
This early-stage trial tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and BCMA, in people with autoimmune blood diseases like ITP, AIHA, or Evans syndrome that have not responded to standard treatments. It aims to reset the immune system and reduce production of harmful antibodies.
Wuhan, HubeiAges 18–75
Hear when a new Evans Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for evans syndrome?
- Yes. Clin2 currently lists 6 recruiting evans syndrome studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a evans syndrome trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a evans syndrome trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.